Dr. James D. Wolfe, MD
Allergy & Immunology (Allergy & Immunology Physician)
4050 Moorpark Ave
San Jose, CA 95117
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1972)
- Years since graduation
- 54
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 745
Licensed in California since 1973, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1972Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
CA license G25149 (first issued 1973; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- El Camino Health Mountain View, CA
- Dominican Hospital Santa Cruz, CA
Medical groups
- UCSF Health Medical Foundation (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 745
- Services billed
- 17,164
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 8,222 | 113 |
| Professional service for preparation and provision of 1 or more antigens | 2,612 | 150 |
| Professional service for multiple injections of allergen | 1,916 | 144 |
| Test to measure expiratory airflow and volume | 864 | 484 |
| Test to measure the level of nitric oxide gas | 827 | 465 |
| Established patient office or other outpatient visit, 30-39 minutes | 808 | 471 |
| Test for allergy using allergenic extract injected into skin | 490 | 82 |
| Established patient office or other outpatient visit, 20-29 minutes | 240 | 224 |
| Professional service for single injection of allergen | 187 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 130 | 130 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in San Jose, CA | 312 |
| Hydroxyzine Hcl Other prescribers in San Jose, CA | 293 |
| Ipratropium Bromide Other prescribers in San Jose, CA | 254 |
| Montelukast Sodium Other prescribers in San Jose, CA | 191 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in San Jose, CA | 170 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in San Jose, CA | 150 |
| Prednisone Other prescribers in San Jose, CA | 149 |
| Clarithromycin | 135 |
| Dupixent Syringe (dupilumab) Other prescribers in San Jose, CA | 104 |
| Alvesco (ciclesonide) | 103 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 81 payments worth $1,752 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $753 |
|---|---|
| GlaxoSmithKline, LLC. | $226 |
| Ars Pharmaceuticals Operations, Inc. | $212 |
| Novartis Pharmaceuticals Corporation | $168 |
| Genzyme Corporation | $114 |
| Regeneron Healthcare Solutions, Inc. | $83.40 |
| Csl Behring | $54.69 |
| Paratek Pharmaceuticals, Inc. | $29.37 |
| Food and Beverage | $1,752 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 7 companies. The companies reported $582,383 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inh…
AstraZeneca Pharmaceuticals LP - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT06102005 - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP - A phase 2 randomized doubleblind placebocontrolled parallelgroup doseranging study to investigate the efficacy and safety of PF07275315 in adult participants with inadequately controlled moderatetosevere asthma
Pfizer Inc. - A phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma
AstraZeneca UK Limited - A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - A randomized, single-dose, double-blind, placebo-controlled, four-way crossover, multicenter bronchoprovocation study comparing the bronchoprotective effects of albuterol sulfate inhalation aerosol (90 mcg, invagen/ci…
Cipla USA Inc. - A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.